Several bispecific antibodies, trispecific antibodies, drug conjugates, and CAR T cell-based studies to target CD33 or CD123 are ongoing but have not reproduced the efficacy seen in acute lymphocytic leukemia (ALL) (13–16). The gene discussed is CD33; the disease is acute lymphoblastic leukemia.